search
Back to results

NightCAP: Reducing Hypnotic Drug Use and Improving Night-time Care (NightCAP)

Primary Purpose

Dementia

Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Hypnotic Medication Review
Structured Sleep Hygiene
Night Time Care Activities Programme
Sponsored by
University of Exeter
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Dementia focused on measuring Dementia, Care Homes, Hypnotic Medication, Night Time Care, Behavioural symptoms, Cost effectiveness

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Care homes (inclusive of residential and nursing) that have failed to meet more than 1 of the 5 CQC care home quality standards check
  • Care homes who have at least 12 eligible care home resident participants
  • Care homes with a minimum of two residents who are eligible to participate in the study taking hypnotic medication
  • Resident participants will have an established or probable diagnosis of dementia
  • Residents will have experienced an episode/occurrence of sleep disturbance behaviour in the past four weeks/two weeks (as reported by care staff)
  • Care home member of staff whose duties include providing care to individuals with dementia
  • Care home care staff are required to have an adequate level of English language to complete all required assessment outcomes
  • Care home care staff participants who will remain in work without plans for extended leave over the study period

Exclusion Criteria:

  • Care homes receiving special support from the local authority
  • Agency care staff
  • Care staff will be able to withdraw from the study at any time

Sites / Locations

  • University of ExeterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control, optimised usual care

Hypnotic Drug Review, Structured Sleep Hygiene and NightCAP

Arm Description

Treatment delivered as usual in the care home

Care homes to receive all three interventions: Hypnotic Drug Review, Structured Sleep Hygiene and NightCAP interventions

Outcomes

Primary Outcome Measures

Sleep Disturbance Inventory SDI
Sleep disturbance behaviour as measured by the Sleep Disturbance Inventory SDI

Secondary Outcome Measures

Change of Hypnotic Drug Use
Hypnotic drug use assessed from the care home Medication Administration Record
Dementia Quality of Life
Quality of life assessed using DEMQOL-Caregiver. Consisting of 32 questions the DEMQOL-Caregiver is an interviewer administered measure, with higher scores indicating better quality of life.
Neuropsychiatric Inventory- Nursing Home (NPI-NH)
The NPI is a validated structured interview assessment with the informant (care staff), that assesses behavioural disturbances in patients with dementia. This 12-item version consists of 10 behavioural and two neurovegetative areas. It provides both a total score as well as scores for a number of sub-scales (e.g. delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, disinhibition, elation/euphoria, apathy/indifference, irritability/lability, aberrant motor activity, sleep, and appetite/eating disorders). The frequency, severity and caregiver distress for each domain are measured. The total possible maximum score is 144. A higher score reflects increased frequency and severity of the disturbances. This specific version is developed for use in care homes, with adapted questions in the standardised interview and the caregiver distress assessment adapted to occupation disruptiveness.
Cohen-Mansfield Agitation Inventory (CMAI)
The CMAI is a caregivers' rating questionnaire to specify agitated behaviour (Cohen-Mansfield et al, 1980). The CMAI consist of 29 items related to agitated behaviour, each of which is rated on a 7- point scale of frequency, from 1= never to 7= several times an hour. The rating is based on a face-to-face interview with a caregiver.
Global Deterioration Scale (GDS)
The GDS is a staging scale indicating deterioration in dementia. The scale details clinical descriptions of seven major distinguishable stages, ranging from normal cognition to severe dementia. Stages 1-3 are the pre dementia stages/ Stages 4-7 reflect the stages of dementia.
Client Service Receipt Inventory (CSRI)
The CSRI is used to estimate the cost of service packages for each participant in the study. Information is collected on the current living arrangements, use of hospital, community-based and day services. The data collected through the CSRI can be used to calculate service costs and total costs of care.
Functional Assessment Staging (FAST)
FAST is a proxy-rated instrument validated for use in people with dementia. It ascertains the severity of dementia in seven stages of functioning.
EQ5D-5L
The EQ5D-5L is a measure of Health Related Quality of Life. The EQ5D-5L consist of the EQ5D descriptive system and the EQ visual analogue scale (EQ VAS).
Abbey Pain Scale
The Abbey Scale is an observation brief indicator of pain for people with end-stage dementia. The scale is rated on six non verbal indicators of pain where 0 is none and 3 is severe
Approached to Dementia Questionnaire (ADQ)
The ADQ is a 19-item instrument. Responses are indicated using a 5-point Likert scale. Higher values represent a better outcome (range from 19-96). The ADQ includes two subscales: person-centredness and hopefulness.
Patient Health Questionnaire 9 (PHQ-9)
A measure of carer mental health and behaviour consisting of 9 questions

Full Information

First Posted
April 28, 2020
Last Updated
July 25, 2022
Sponsor
University of Exeter
Collaborators
King's College London, University of East Anglia, Aston University
search

1. Study Identification

Unique Protocol Identification Number
NCT04373668
Brief Title
NightCAP: Reducing Hypnotic Drug Use and Improving Night-time Care
Acronym
NightCAP
Official Title
Reducing Hypnotic Drug Use and Improving Night-time Care for People Living With Dementia in Care Homes (NightCAP): A Randomised Factorial Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 1, 2021 (Actual)
Primary Completion Date
April 30, 2023 (Anticipated)
Study Completion Date
April 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Exeter
Collaborators
King's College London, University of East Anglia, Aston University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Dementia is a devastating condition characterised by progressive loss of cognition leading to loss of independence and eventually death. One major unmet need, which remains a critical challenge for care provision, is the management of night-time care and sleep-related symptoms in people with dementia living in care homes. The causes and impacts of sleep disturbances in people with dementia in care homes are complex and multi-faceted, indicating the need of a whole-systems approach to the issue. It will require a tailored, person-centred approach which accounts for the environmental, personal and clinical factors contributing to the symptoms. The aim of this study is to evaluate the NightCAP intervention to improve treatment of sleep disturbance in people with dementia in care homes, with the goal of reducing sleep disturbance behaviour and reducing the use of hypnotic drugs. This will provide robust evidence to support guidance on night time care and improving hypnotic drug prescribing, both of which are major unmet needs in the care of people with dementia.
Detailed Description
The main objective of this current study is to explore the effectiveness of specific benefits of key components of the Night Time Care Activities Programme- NightCAP. Particularly elements of sleep hygiene and personalised night-time care planning. There may also be additional benefit in combining NightCAP elements with pharmacological review protocol to enable management of all major contributing factors in sleep disturbance. This cluster-randomised trial will be delivered in 24 UK care homes. Participants will be individuals living with dementia and experiencing sleep disturbance, as well as staff who care for them. Homes will be randomly allocated to one of two arms: optimised usual care or the intervention arm. All homes will receive an optimised person-centred care module. The NightCAP intervention programme consists of three key elements: (i) personalised night-time care planning (supported staff training and implementation); (ii) structured sleep hygiene (staff training); and (iii) hypnotic drug review protocol (GP fact sheet and staff training). The primary outcome will be sleep disturbance at the end of the intervention. Secondary outcomes will be hypnotic drug use, quality of life, resident falls, job satisfaction, burden and coping in care staff, and cost effectiveness.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dementia
Keywords
Dementia, Care Homes, Hypnotic Medication, Night Time Care, Behavioural symptoms, Cost effectiveness

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
720 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control, optimised usual care
Arm Type
No Intervention
Arm Description
Treatment delivered as usual in the care home
Arm Title
Hypnotic Drug Review, Structured Sleep Hygiene and NightCAP
Arm Type
Experimental
Arm Description
Care homes to receive all three interventions: Hypnotic Drug Review, Structured Sleep Hygiene and NightCAP interventions
Intervention Type
Behavioral
Intervention Name(s)
Hypnotic Medication Review
Intervention Description
A training programme focused providing guidance on the review and withdrawal process of hypnotic drugs.
Intervention Type
Behavioral
Intervention Name(s)
Structured Sleep Hygiene
Intervention Description
Training module on the principle of good sleep hygiene
Intervention Type
Behavioral
Intervention Name(s)
Night Time Care Activities Programme
Intervention Description
Training and support package to assist in the development of a personalised night time care plan and support the implementation and dissemination of information within the care home environment
Primary Outcome Measure Information:
Title
Sleep Disturbance Inventory SDI
Description
Sleep disturbance behaviour as measured by the Sleep Disturbance Inventory SDI
Time Frame
From baseline and immediately after intervention
Secondary Outcome Measure Information:
Title
Change of Hypnotic Drug Use
Description
Hypnotic drug use assessed from the care home Medication Administration Record
Time Frame
From baseline, immediately after intervention and at four months follow-up
Title
Dementia Quality of Life
Description
Quality of life assessed using DEMQOL-Caregiver. Consisting of 32 questions the DEMQOL-Caregiver is an interviewer administered measure, with higher scores indicating better quality of life.
Time Frame
From baseline, immediately after intervention and at four months follow-up
Title
Neuropsychiatric Inventory- Nursing Home (NPI-NH)
Description
The NPI is a validated structured interview assessment with the informant (care staff), that assesses behavioural disturbances in patients with dementia. This 12-item version consists of 10 behavioural and two neurovegetative areas. It provides both a total score as well as scores for a number of sub-scales (e.g. delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, disinhibition, elation/euphoria, apathy/indifference, irritability/lability, aberrant motor activity, sleep, and appetite/eating disorders). The frequency, severity and caregiver distress for each domain are measured. The total possible maximum score is 144. A higher score reflects increased frequency and severity of the disturbances. This specific version is developed for use in care homes, with adapted questions in the standardised interview and the caregiver distress assessment adapted to occupation disruptiveness.
Time Frame
From baseline, immediately after intervention and at four months follow-up
Title
Cohen-Mansfield Agitation Inventory (CMAI)
Description
The CMAI is a caregivers' rating questionnaire to specify agitated behaviour (Cohen-Mansfield et al, 1980). The CMAI consist of 29 items related to agitated behaviour, each of which is rated on a 7- point scale of frequency, from 1= never to 7= several times an hour. The rating is based on a face-to-face interview with a caregiver.
Time Frame
From baseline, immediately after intervention and at four months follow-up
Title
Global Deterioration Scale (GDS)
Description
The GDS is a staging scale indicating deterioration in dementia. The scale details clinical descriptions of seven major distinguishable stages, ranging from normal cognition to severe dementia. Stages 1-3 are the pre dementia stages/ Stages 4-7 reflect the stages of dementia.
Time Frame
From baseline, immediately after intervention and at four months follow-up
Title
Client Service Receipt Inventory (CSRI)
Description
The CSRI is used to estimate the cost of service packages for each participant in the study. Information is collected on the current living arrangements, use of hospital, community-based and day services. The data collected through the CSRI can be used to calculate service costs and total costs of care.
Time Frame
From baseline, immediately after intervention and at four months follow-up
Title
Functional Assessment Staging (FAST)
Description
FAST is a proxy-rated instrument validated for use in people with dementia. It ascertains the severity of dementia in seven stages of functioning.
Time Frame
From baseline, immediately after intervention and at four months follow-up
Title
EQ5D-5L
Description
The EQ5D-5L is a measure of Health Related Quality of Life. The EQ5D-5L consist of the EQ5D descriptive system and the EQ visual analogue scale (EQ VAS).
Time Frame
From baseline, immediately after intervention and at four months follow-up
Title
Abbey Pain Scale
Description
The Abbey Scale is an observation brief indicator of pain for people with end-stage dementia. The scale is rated on six non verbal indicators of pain where 0 is none and 3 is severe
Time Frame
From baseline, immediately after intervention and at four months follow-up
Title
Approached to Dementia Questionnaire (ADQ)
Description
The ADQ is a 19-item instrument. Responses are indicated using a 5-point Likert scale. Higher values represent a better outcome (range from 19-96). The ADQ includes two subscales: person-centredness and hopefulness.
Time Frame
From baseline, immediately after intervention and at four months follow-up
Title
Patient Health Questionnaire 9 (PHQ-9)
Description
A measure of carer mental health and behaviour consisting of 9 questions
Time Frame
From baseline, immediately after intervention and at four months follow-up

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Care homes (inclusive of residential and nursing) that have failed to meet more than 1 of the 5 CQC care home quality standards check Care homes who have at least 12 eligible care home resident participants Care homes with a minimum of two residents who are eligible to participate in the study taking hypnotic medication Resident participants will have an established or probable diagnosis of dementia Residents will have experienced an episode/occurrence of sleep disturbance behaviour in the past four weeks/two weeks (as reported by care staff) Care home member of staff whose duties include providing care to individuals with dementia Care home care staff are required to have an adequate level of English language to complete all required assessment outcomes Care home care staff participants who will remain in work without plans for extended leave over the study period Exclusion Criteria: Care homes receiving special support from the local authority Agency care staff Care staff will be able to withdraw from the study at any time
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kayleigh Nunez
Phone
01392724464
Email
k.nunez@exeter.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anne Corbett
Organizational Affiliation
University of Exeter
Official's Role
Study Chair
Facility Information:
Facility Name
University of Exeter
City
Exeter
State/Province
Devon
ZIP/Postal Code
EX1 2LU
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kayleigh Nunez
Email
k.nunez@exeter.ac.uk

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

NightCAP: Reducing Hypnotic Drug Use and Improving Night-time Care

We'll reach out to this number within 24 hrs